Long-term clinical response in Leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: A case report

Clinical Breast Cancer

Volumn 7, Issue 2, 2006, Pages 164-166

  Tham, Yee Lu ^a   Hinckley, Lisa ^b   Teh, Bin S ^b   Elledge, Richard ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Blood brain barrier; Central nervous system

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CYTOLOGY; DIARRHEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HUMAN; LUMBAR PUNCTURE; LYMPH NODE METASTASIS; MASTECTOMY; MEMBRANE PERMEABILITY; MENINGEAL METASTASIS; NAUSEA AND VOMITING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; SYMPTOM; TREATMENT OUTCOME; TUMOR VOLUME; WEAKNESS;

EID: 33745880658     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.028     Document Type: Article

References (13)

1. Boogerd W, Dorresteijn LD, van Der Sande JJ, et al. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000; 55:117-119.
2. Yap HY, Yap BS, Tashima CK, et al. Meningeal carcinomatosis in breast cancer. Cancer 1978; 42:283-286.
3. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49:759-772.
4. Jaeckle KA, Phuphanich S, Bent MJ, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001; 84:157-163.
5. Ozdogan M, Samur M, Bozcuk ES, et al. Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol 2003; 33:229-231.
6. Wang ML, Yung WK, Royce ME, et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001; 24:421-424.
7. Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro-oncol 2004; 6:63-64.
8. Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 2003; 65:167-172.
9. Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12:1247-1254.
10. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-493.
11. McEvoy GK. Capecitabine. In: AHFS Drug Information. Bethesda, Md: American Society of Health-System Pharmacists, Inc; 2002:916-921.
12. Kim JS, Cho MJ, Song KS, et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54:403-408.
13. Corvo R, Pastrone I, Scolaro T, et al. Radiotherapy and oral capecitabine in the preoperative treatment of patients with rectal cancer: rationale, preliminary results and perspectives. Tumori 2003; 89:361-367.